Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1

Tsutamoto, Takayoshi; Wada, Atsuyuki; Maeda, Keiko; Hisanaga, Tomoko; Mabuchi, Naoko; Hayashi, Meiso; Ohnishi, Masato; Sawaki, Masahide; Fujii, Masazumi; Horie, Hajime; Sugimoto, Yukihiko; Kinoshita, Masahiko

doi:10.1053/euhj.1999.1746

Cited by 217 publications

(139 citation statements)

References 28 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…Elevated MMP‐9 levels may help identify patients at risk before an increase occurs in ventricular pressure overload, which reflects ongoing ventricular remodeling. The value of BNP levels for guiding therapy in addition to clinical symptom‐based treatment seems to be limited,9, 10, 11, 21 despite the undisputed diagnostic and prognostic importance of these values 6, 7, 8. The benefits of predicting HF events may be offset by non‐HF events.…”

Section: Discussionmentioning

confidence: 99%

“…Plasma levels of BNP were measured using a commercially available radioimmunoassay kit (Shionogi, Osaka, Japan), and plasma levels of NA were measured with high‐performance liquid chromatography 6. Plasma NA concentration provides prognosis utility in congestive HF patients 19…”

Section: Methodsmentioning

confidence: 99%

“…Of these, elevated plasma concentrations of brain natriuretic peptide (BNP) show notable associations with development of left ventricular dysfunction and HF 5. Although elevated BNP concentrations have diagnostic and prognostic importance,6, 7, 8 whether intense therapy for HF guided by BNP values is superior to therapy guided by clinical symptoms is unclear 9, 10, 11. BNP play important roles in maintaining cardiorenal homeostasis under physiological and pathological conditions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure

et al. 2017

View full text Add to dashboard Cite

AimsMatrix metalloproteinase (MMP) is up‐regulated during heart failure (HF) and influences ventricular remodeling. We hypothesized that disparity between MMP‐9 and tissue inhibitors of MMP‐1 (TIMP‐1) results in clinical manifestations and is related to prognostic risk in patients with chronic HF.Methods and resultsPlasma levels of MMP‐9, TIMP‐1, and brain natriuretic peptide (BNP) were measured in 173 patients with chronic HF. Combined endpoints of worsening HF events were assessed during follow‐up (median 109 months). MMP‐9 and TIMP‐1 levels and the MMP‐9/TIMP‐1 ratio increased with increasing severity of the New York Heart Association class (P for trend = 0.003, 0.011, and 0.005, respectively). Patients with HF events (n = 35) had significantly higher MMP‐9 than those without HF events (P = 0.004). Kaplan–Meier analysis demonstrated a higher probability of HF events with high MMP‐9 values (>23.2 ng/mL; P = 0.005). A multivariate Cox proportional hazard model showed that high MMP‐9 values were an independent predictor of HF events (hazard ratio, 3.73; 95% confidence interval (CI), 1.03–13.46; P = 0.043). In patients with lower BNP levels (≤210 pg/mL), the adjusted hazard ratio for HF events was 3.63 (95% CI, 1.20–11.02; P = 0.023) among patients with high MMP‐9 values compared with patients with low BNP and low MMP‐9 values.ConclusionsMMP‐9 and TIMP‐1 levels correlate with the severity of chronic HF. MMP‐9 is a strong predictor of HF events, suggesting that a disparity between MMP‐9 and TIMP‐1 levels and increased MMP‐9 levels may help predict HF events.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In patients with CHF, high plasma levels of PRC, Ang II, ALD and BNP were associated with poor prognosis. 17,18,28,29 Most biomarkers, except Ang II, did not change after replacement of candesartan with olmesartan. A high plasma Ang II level is a prognostic predictor in asymptomatic CHF patients 28 and in mild-to-moderate CHF patients.…”

Section: Discussionmentioning

confidence: 99%

“…17,18,28,29 Most biomarkers, except Ang II, did not change after replacement of candesartan with olmesartan. A high plasma Ang II level is a prognostic predictor in asymptomatic CHF patients 28 and in mild-to-moderate CHF patients. 29 Recently, it was reported that there may be differential effects of various ARBs on prognosis in patients with CHF.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension

et al. 2009

View full text Add to dashboard Cite

In general, treatment with most angiotensin receptor blockers (ARBs) increases plasma angiotensin II (Ang II) level because of a lack of negative feedback on renin activity. Olmesartan is a potential ARB inducing activation of angiotensin-converting enzyme 2 (ACE2) that hydrolyzes Ang II to Ang 1-7, and has shown a beneficial effect on ventricular remodeling. Indeed, a previous study reported that olmesartan treatment resulted in decreased plasma levels of Ang II and aldosterone. However, there has not yet been a study showing the relationship of chronic effects of olmesartan on Ang II and the left ventricular mass index (LVMI) in comparison with those of other ARB. A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n¼25): continuous candesartan treatment at a stable dose; and olmesartan group (n¼25): candesartan (8 mg day À1 ) was changed to olmesartan given at a dose of 20 mg day À1 . There was no difference in the baseline characteristics between the two groups. In the control group, there were no significant changes in blood pressure, LVMI or biomarkers during 12 months of study. In the olmesartan group, blood pressure did not change and plasma levels of Ang II decreased during 12 months of study, whereas LVMI was significantly decreased after 12 months (135 ± 36 vs. 123 ± 29 g m À2 ; Po0.01). These findings indicate that replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension.

show abstract

Preoperative Evaluation for Major Noncardiac Surgery

Hernandez

Newby²,

O’Connor³

2004

Arch Intern Med

View full text Add to dashboard Cite

The number of patients undergoing major noncardiac surgery has steadily increased over the last decade. Cardiovascular complications are important and often feared by patients, surgeons, and anesthesiologists. Although preoperative risk assessment has improved since Goldman and colleagues published their landmark article that introduced the Multifactorial Index of Cardiac Risk 25 years ago, it continues to require modification, especially with the increasing prevalence of heart failure and the increase in procedures performed in the elderly. This review will summarize preoperative assessment and perioperative management with an emphasis on heart failure.

show abstract

Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1

Abstract: These results indicate that a high plasma brain natriuretic peptide level provides information about mortality and morbidity in patients with asymptomatic or minimally symptomatic left ventricular dysfunction.

Cited by 217 publications

References 28 publications

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure

Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension

Preoperative Evaluation for Major Noncardiac Surgery

Contact Info

Product

Resources

About